19 August 2026
FDA clears PrecivityAD2 as substantially equivalent
K253240 was decided Substantially Equivalent (SESE) on 08/19/2026.
The full briefing is in the app.
19 August 2026
K253240 was decided Substantially Equivalent (SESE) on 08/19/2026.
The full briefing is in the app.